Robert B. Bazemore

Insider Reports History

Identity Names, identifiers, and filing context for this profile. 1 identity field
Reporting-owner location
Lexington, MA
SEC source record Original filing metadata and source links for verification. 1 source field
Latest reporting-owner signature
/s/ Felecia Ettenberg, Attorney-in-Fact for Robert B. Bazemore
Source: Latest parsed Forms 3/4/5 signature
Source evidence Original filing metadata and source links for verification. 1 source field
Transaction source note
Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for Robert B. Bazemore

Form 4 holding Director

ARDELYX, INC.

Security class
Stock Option (Right to Buy)
Shares / value
39,715
Estimated value
$93,364
Report date
16 Jun 2026
Price
$2.32
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

Akari Therapeutics Plc

Security class
American Depositary Shares representing Ordinary Shares
Shares / value
44,642
Estimated value
$49,999
Report date
20 Mar 2025
Price
$1.12
Ownership
Direct
Form 4 holding Director

Akari Therapeutics Plc

Security class
Series A Warrants (Right to Buy)
Shares / value
44,642
Estimated value
$49,999
Report date
06 Mar 2025
Price
$1.12
Ownership
Direct
Underlying class
American Depositary Shares representing Ordinary Shares
Underlying amount
Form 4 holding Director

Akari Therapeutics Plc

Security class
Series B Warrants (Right to Buy)
Shares / value
44,642
Estimated value
$49,999
Report date
06 Mar 2025
Price
$1.12
Ownership
Direct
Underlying class
American Depositary Shares representing Ordinary Shares
Underlying amount
Form 4 holding Director

Akari Therapeutics Plc

Security class
Pre-Funded Warrants to purchase ADRs
Shares / value
30,932
Estimated value
$12,499
Report date
16 Dec 2025
Price
$0.4041
Ownership
Direct
Underlying class
American Depositary Shares representing Ordinary Shares
Underlying amount
Form 4 holding Director

Akari Therapeutics Plc

Security class
Stock Option (Right to Buy)
Shares / value
225,000
Estimated value
Report date
20 Mar 2025
Price
Ownership
Direct
Underlying class
American Depositary Shares representing Ordinary Shares
Underlying amount
Form 4 holding Director

Akari Therapeutics Plc

Security class
Warrants to purchase American Depositary Shares ("ADRs")
Shares / value
123,731
Estimated value
Report date
16 Dec 2025
Price
Ownership
Direct
Underlying class
American Depositary Shares representing Ordinary Shares
Underlying amount
Form 4 holding Director

Akari Therapeutics Plc

Security class
Warrants to purchase ADRs
Shares / value
30,932
Estimated value
Report date
16 Dec 2025
Price
Ownership
Direct
Underlying class
American Depositary Shares representing Ordinary Shares
Underlying amount

Insider Reports Filed by Robert B. Bazemore

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .